These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34653057)

  • 41. Adoption of Lutetium-
    Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K; Mix M; Meyer PT; Ruf J
    Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of PSMA-Targeted Molecular Radioligand Therapy with
    Calais J; Czernin J; Thin P; Gartmann J; Nguyen K; Armstrong WR; Allen-Auerbach M; Quon A; Bahri S; Gupta P; Gardner L; Dahlbom M; He B; Esfandiari R; Ranganathan D; Herrmann K; Eiber M; Fendler WP; Delpassand E
    J Nucl Med; 2021 Oct; 62(10):1447-1456. PubMed ID: 34272322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
    Wrenger R; Jüptner M; Marx M; Zhao Y; Zuhayra M; Caliebe A; Osmonov D; Lützen U
    BMC Urol; 2022 Jul; 22(1):96. PubMed ID: 35788220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
    Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
    Zhang J; Kulkarni HR; Singh A; Baum RP
    Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.
    Parveen A; Fatima A; Fatima I; Khan IU; Shahid A
    Nucl Med Commun; 2023 Oct; 44(10):876-887. PubMed ID: 37440195
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1754-1764. PubMed ID: 34842950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
    J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of a Prospective Phase 2 Pilot Trial of
    Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
    Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
    Ferdinandus J; Eppard E; Gaertner FC; Kürpig S; Fimmers R; Yordanova A; Hauser S; Feldmann G; Essler M; Ahmadzadehfar H
    J Nucl Med; 2017 Feb; 58(2):312-319. PubMed ID: 27587707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
    Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ
    Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extensive
    Schäfer H; Mayr S; Büttner-Herold M; Knorr K; Steinhelfer L; Böger CA; Gschwend JE; Heemann U; Eiber M; Schmaderer C; Tauber R
    Eur Urol; 2023 May; 83(5):385-390. PubMed ID: 35688660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early molecular imaging response assessment based on determination of total viable tumor burden in [
    Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
    Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.